MAY 18, 2019 04:44 PM PDT

How a Cancer Drug Inhibits DNA Repair in Cancer Cells

WRITTEN BY: Nouran Amin

In a study published in the journal Science Translational Medicine, combing a certain cancer drug with other agents could potentially deliver a lethal blow in cancer that uses a specific pathway to create DNA repair cells.

Learn more about DNA repair and damage:

That drug is called Cediranib and when combined with another cancer agent known as olaparib (registered as Lynparza) can be effective in a specific form of ovarian cancer.

"The use of cediranib to help stop cancer cells from repairing damage to their DNA could potentially be useful in a number of cancers that rely on the pathway the drug targets," said the study's lead investigator, Alanna Kaplan. "If we could identify the cancers that depend on this pathway, we may be able to target a number of tumors."

Cediranib inhibits vascular endothelial growth factor (VEGF) receptors that stimulate the formation of blood vessels that support tumor growth. However, it has been less beneficial than the FDA-approved Avastin--an VEGF pathway inhibitor. On the other hand, Olaparib--the first approved DNA repair drug, inhibits a DNA repair enzyme called PARP which eradicates cancer cells with DNA defects in DNA repair from mutations in two DNA repair genes--BRCA1 and BRCA2.

DNA illustration. Credit: © Kirsty Pargeter / Adobe Stock

"There is a lot of interest in the cancer field in developing DNA repair inhibitors because they will greatly help treatments, like radiotherapy and chemotherapy, that aim to destroy DNA in cancer cells," said the senior author of the study, Peter M. Glazer, M.D. "People are recognizing that manipulating DNA repair could be very advantageous to boosting the benefit of traditional cancer treatment."

However, the combination of cediranib and olaparib was effective in ovarian cancers that did not include BRCA1/BRCA2 mutations. This lead to the launch of several clinical trials that tested the drug in duo for different types of cancers, such as prostate and lung cancer.

"The goal now is to investigate how we can broaden the potential of this synthetic lethality to other cancer types," said Glazer.

Source: Yale University News

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 18, 2019
Immunology
JUN 18, 2019
Anti-Inflammatory Meds without Side Effects, Please
Drugs such as ibuprofen or aspirin that relieve pain and lower fever are among the most frequently used drugs worldwide....
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Bisphosphonates increasingly prescribed to the women most likely to benefit
Recently, there has been a trend in the age of women who have been prescribed bisphosphonates (BPs) for the treatment osteoporosis and the prevention of fr...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Synthetic Oxytocin for Obesity Treatment
According to recent research, the hormone oxytocin reduced the communication in different regions of the brain involved in the cognitive, sensory and emoti...
JUN 18, 2019
Genetics & Genomics
JUN 18, 2019
The Power and Responsibility of Using CRISPR
      What makes CRISPR so powerful is that it is easy for any molecular or genetic scientist to use, and it works on almost every cell...
JUN 18, 2019
Microbiology
JUN 18, 2019
Fecal Transplants Recommended for Recurrent C. diff Infections
While hospitals are intended to be places of healing, people can acquire nasty infections with drug-resistant bacteria during a stay there....
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Drug Treatment for Social Anxiety Proves Insufficient
In a Japanese study published in the journal Psychotherapy and Psychosomatics, antidepressant drugs targeted for treating patients with a social anxiety di...
Loading Comments...